Stockscreener 앱 받기
66.33
0.27%
0.22
시간 외 거래:
66.55
0.22
+0.33%
Dexcom Inc 주식(DXCM)의 최신 뉴스
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U - Morningstar
DXCMDexCom Reports Second Quarter 2018 Financial Results - ADVFN
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB - ADVFN
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness Week to Close the Glucose Knowledge Gap - Investegate
DexCom Execs Sued For Allegedly Misleading Growth Claims - Law360
DexCom (NasdaqGS:DXCM) Gains FDA Clearance For Dexcom G7 System - Yahoo Finance
Alert on DexCom from law firm's press release withdrawn - marketscreener.com
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating - MarketScreener
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Resu - GuruFocus
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring - Clinical Advisor
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Results | DXCM Stock News - GuruFocus
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance - MSN
FDA clears Dexcom G7 15 Day - BioWorld MedTech
What to Expect From DexCom's Next Quarterly Earnings Report - Nasdaq
What Does the Market Think About DexCom? - Benzinga
DexCom signals 14% revenue growth target for 2025 with new product launches and expanded coverage - MSN
What To Expect From DexCom's Next Quarterly Earnings Report - Barchart.com
DexCom (DXCM) Faces Market Challenges Amid Strategic Changes - GuruFocus
DexCom (DXCM) Anticipates Growth Driven by Strategic Initiatives - GuruFocus
DexCom (DXCM) Gains on FDA Approval for G7 15 Day Monitoring Sys - GuruFocus
FDA clears Dexcom G7 15-Day continuous glucose monitor - TechTarget
Mizuho Initiates Coverage of DexCom (XTRA:DC4) with Outperform Recommendation - Nasdaq
Dexcom G7 15 Day CGM system cleared by FDA for adults - Investing.com South Africa
Dexcom G7 15 Day CGM System Cleared by FDA - Patient Care Online
DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings ReportHagens Berman - ACCESS Newswire
Dexcom nets FDA clearance for 15-day CGM - MedTech Dive
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomPanhandle - Panhandle - News Channel
Press Release Distribution & PR Platform - ACCESS Newswire
FDA Approves New DexCom Diabetes Device - Yahoo Finance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - Benzinga
Stifel maintains DexCom stock Buy rating, $100 target post FDA nod - Investing.com Australia
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance - Barron's
Dexcom wins FDA nod for 15-day CGM - MassDevice
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - ACCESS Newswire
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction - The Motley Fool
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - Benzinga
DexCom (DXCM) Receives FDA Clearance for Enhanced Glucose Monito - GuruFocus
DexCom Says G7 15 Day Continuous Glucose Monitoring System Gets US FDA Clearance - marketscreener.com
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wea - GuruFocus
Dexcom stock rises on FDA nod for new CGM (DXCM:NASDAQ) - Seeking Alpha
FDA OKs Dexcom G7 15-Day Continuous Glucose Monitor - Medical Product Outsourcing
DexCom shares rise on FDA clearance for new CGM system - Investing.com Australia
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Dexcom
Mizuho Initiates Coverage of DexCom (DXCM) with Outperform Recommendation - Nasdaq
What 6 Analyst Ratings Have To Say About DexCom - Benzinga
Mizuho Initiates DexCom at Outperform With $85 Price Target - marketscreener.com
1.93%
자본화:
|
볼륨(24시간):